TherapeuticsMD, Inc. (NASDAQ: TXMD)

TherapeuticsMD, Inc. (TXMD), a pharmaceutical royalty company, generates revenue from royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company operates in the pharmaceutical industry and is based in the United States.

TherapeuticsMD's main business activities involve the development, licensing, and commercialization of pharmaceutical products that address the unmet medical needs of women. The company's primary products include IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. IMVEXXY is a pharmaceutical product used to treat moderate-to-severe dyspareunia (vaginal pain associated with sexual activity) due to menopause, while BIJUVA is used to treat moderate-to-severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus. ANNOVERA is a one-year ring-shaped contraceptive vaginal system that is the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent pregnancy for up to a total of 13 cycles (one year). The company's prenatal vitamin products are prescription prenatal vitamin products sold under the vitaMedMD brand name and authorized generic formulations of some of these products under the BocaGreenMD prenatal name.

TherapeuticsMD generates revenue primarily from royalties on its licensed products. The company's primary revenue sources include IMVEXXY, BIJUVA, and its prescription prenatal vitamin products. IMVEXXY and BIJUVA are licensed to Mayne Pharma for commercialization in the United States and its territories, and the company has also entered into licensing agreements with third parties to market and sell these products outside of the U.S. ANNOVERA is licensed to Mayne Pharma for commercialization in the United States and its territories, while the company's prenatal vitamin products are licensed to Mayne Pharma for commercialization in the United States and its territories.

TherapeuticsMD operates in a highly competitive industry, with key competitors including other pharmaceutical companies and generic manufacturers. The company's competitive advantages include its focus on women's health, its development of innovative pharmaceutical products, and its licensing agreements with experienced commercialization partners. Despite these advantages, the company's position within the industry is subject to various risks and uncertainties, including regulatory risks, competition, and changes in healthcare laws and regulations.

The company's customers include Mayne Pharma, which has been granted exclusive licenses to commercialize IMVEXXY, BIJUVA, and ANNOVERA, as well as third-party companies that have entered into licensing agreements with the company to market and sell its products outside of the U.S.

TherapeuticsMD's brand names and trade names of its products include IMVEXXY, BIJUVA, ANNOVERA, vitaMedMD, and BocaGreenMD.